Stefan K James

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9294855/publications.pdf

Version: 2024-02-01

272 papers	39,201 citations	20815 60 h-index	2747 192 g-index
278 all docs	278 docs citations	278 times ranked	26559 citing authors

#	Article	IF	Citations
1	2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal, 2018, 39, 119-177.	2.2	7,100
2	Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. New England Journal of Medicine, 2009, 361, 1045-1057.	27.0	6,019
3	2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal, 2020, 41, 407-477.	2.2	4,210
4	Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 2010, 31, 2501-2555.	2.2	2,649
5	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Heart Journal, 2018, 39, 213-260.	2.2	2,246
6	Long-Term Outcomes with Drug-Eluting Stents versus Bare-Metal Stents in Sweden. New England Journal of Medicine, 2007, 356, 1009-1019.	27.0	1,113
7	Thrombus Aspiration during ST-Segment Elevation Myocardial Infarction. New England Journal of Medicine, 2013, 369, 1587-1597.	27.0	943
8	Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet, The, 2017, 389, 1025-1034.	13.7	840
9	Instantaneous Wave-free Ratio versus Fractional Flow Reserve to Guide PCI. New England Journal of Medicine, 2017, 376, 1813-1823.	27.0	740
10	N -Terminal Proâ€“Brain Natriuretic Peptide and Other Risk Markers for the Separate Prediction of Mortality and Subsequent Myocardial Infarction in Patients With Unstable Coronary Artery Disease. Circulation, 2003, 108, 275-281.	1.6	540
11	The Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART). Heart, 2010, 96, 1617-1621.	2.9	537
12	Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. Circulation, 2019, 140, 240-261.	1.6	428
13	Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. American Heart Journal, 2009, 157, 599-605.	2.7	363
14	Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes in Relation to Renal Function. Circulation, 2010, 122, 1056-1067.	1.6	354
15	Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. European Heart Journal, 2019, 40, 2632-2653.	2.2	335
16	Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA. New England Journal of Medicine, 2020, 383, 207-217.	27.0	333
17	Improved outcomes in patients with ST-elevation myocardial infarction during the last 20â€‰years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995â€“2014. European Heart Journal, 2017, 38, 3056-3065.	2.2	302
18	International Expert Consensus on Switching Platelet P2Y ₁₂ Receptorâ€“Inhibiting Therapies. Circulation, 2017, 136, 1955-1975.	1.6	293

#	Article	IF	Citations
19	Oxygen Therapy in Suspected Acute Myocardial Infarction. New England Journal of Medicine, 2017, 377, 1240-1249.	27.0	276
20	Reperfusion therapy for ST elevation acute myocardial infarction 2010/2011: current status in 37 ESC countries. European Heart Journal, 2014, 35, 1957-1970.	2.2	275
21	Acute myocardial infarction: a comparison of short-term survival in national outcome registries in Sweden and the UK. Lancet, The, 2014, 383, 1305-1312.	13.7	258
22	Quantitative Assessment of MyocardialÂPerfusion in the Detection of Significant Coronary Artery Disease. Journal of the American College of Cardiology, 2014, 64, 1464-1475.	2.8	253
23	Registry-based randomized clinical trialsâ€"a new clinical trial paradigm. Nature Reviews Cardiology, 2015, 12, 312-316.	13.7	236
24	Thrombus Aspiration in ST-Segmentâ€"Elevation Myocardial Infarction. Circulation, 2017, 135, 143-152.	1.6	233
25	Bivalirudin versus Heparin Monotherapy in Myocardial Infarction. New England Journal of Medicine, 2017, 377, 1132-1142.	27.0	228
26	Evidence for obesity paradox in patients with acute coronary syndromes: a report from the Swedish Coronary Angiography and Angioplasty Registry. European Heart Journal, 2013, 34, 345-353.	2.2	224
27	Long-Term Safety and Efficacy of Drug-Eluting versus Bare-Metal Stents in Sweden. New England Journal of Medicine, 2009, 360, 1933-1945.	27.0	223
28	Dual Antiplatelet Therapy Duration BasedÂon Ischemic and Bleeding Risks After CoronaryÂStenting. Journal of the American College of Cardiology, 2019, 73, 741-754.	2.8	218
29	Rapid Endovascular Catheter Core Cooling Combined With Cold Saline as an Adjunct toÂPercutaneous Coronary Intervention for theÂTreatment of Acute Myocardial Infarction. Journal of the American College of Cardiology, 2014, 63, 1857-1865.	2.8	203
30	Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet, The, 2017, 389, 1799-1808.	13.7	174
31	Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. European Heart Journal, 2014, 35, 2083-2093.	2.2	171
32	Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. European Heart Journal, 2011, 32, 2945-2953.	2.2	169
33	Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet, The, 2019, 394, 1169-1180.	13.7	155
34	Mortality with Paclitaxel-Coated Devices in Peripheral Artery Disease. New England Journal of Medicine, 2020, 383, 2538-2546.	27.0	144
35	Troponin t levels and risk of 30-day outcomes in patients with the acute coronary syndrome: prospective verification in the gusto-iv trial. American Journal of Medicine, 2003, 115, 178-184.	1.5	141
36	Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry. European Heart Journal, 2016, 37, 3335-3342.	2.2	138

#	Article	IF	Citations
37	Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. European Heart Journal, 2016, 37, 1325-1333.	2.2	137
38	Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and a History of Stroke or Transient Ischemic Attack. Circulation, 2012, 125, 2914-2921.	1.6	112
39	Relations between implementation of new treatments and improved outcomes in patients with non-ST-elevation myocardial infarction during the last 20 years: experiences from SWEDEHEART registry 1995 to 2014. European Heart Journal, 2018, 39, 3766-3776.	2.2	112
40	Adaptation of the Charlson Comorbidity Index for Register-Based Research in Sweden. Clinical Epidemiology, 2021, Volume 13, 21-41.	3.0	111
41	Stent Thrombosis in New-Generation Drug-Eluting Stents in Patients With STEMI Undergoing Primary PCI. Journal of the American College of Cardiology, 2014, 64, 16-24.	2.8	110
42	Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy. European Heart Journal, 2018, 39, 1078-1085.	2.2	109
43	Chronic Total Occlusions in Sweden â€“ A Report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). PLoS ONE, 2014, 9, e103850.	2.5	108
44	Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. European Heart Journal, 2015, 36, 1901-1912.	2.2	107
45	EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic. European Heart Journal, 2020, 41, 1839-1851.	2.2	106
46	Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet, The, 2016, 387, 136-145.	13.7	96
47	Comparison of hospital variation in acute myocardial infarction care and outcome between Sweden and United Kingdom: population based cohort study using nationwide clinical registries. BMJ, The, 2015, 351, h3913.	6.0	94
48	Comparative Efficacy and Safety of Oral P2Y ₁₂ Inhibitors in Acute Coronary Syndrome. Circulation, 2020, 142, 150-160.	1.6	93
49	Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. American Heart Journal, 2015, 169, 899-905.e1.	2.7	91
50	Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. Nature Reviews Cardiology, 2020, 17, 242-257.	13.7	87
51	Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study. European Heart Journal, 2021, 42, 243-252.	2.2	84
52	Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. European Journal of Preventive Cardiology, 2015, 22, 734-742.	1.8	82
53	Complete vs Culprit-Lesion-Only Revascularization for ST-Segment Elevation Myocardial Infarction. JAMA Cardiology, 2020, 5, 881.	6.1	82
54	Gender Differences in Outcomes and Predictors of All-Cause Mortality After Percutaneous Coronary Intervention (Data from United Kingdom and Sweden). American Journal of Cardiology, 2017, 119, 210-216.	1.6	81

#	Article	IF	Citations
55	Intravascular Ultrasound Guidance Is Associated With Better Outcome in Patients Undergoing Unprotected Left Main Coronary Artery Stenting Compared With Angiography Guidance Alone. Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	78
56	Registry-Based Pragmatic Trials in Heart Failure: Current Experience and Future Directions. Current Heart Failure Reports, 2017, 14, 59-70.	3.3	72
57	Bleeding avoidance strategies in percutaneous coronary intervention. Nature Reviews Cardiology, 2022, 19, 117-132.	13.7	71
58	The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. European Heart Journal, 2014, 35, 1541-1550.	2.2	70
59	Ticagrelor Added to Aspirin in Acute Nonsevere Ischemic Stroke or Transient Ischemic Attack of Atherosclerotic Origin. Stroke, 2020, 51, 3504-3513.	2.0	67
60	Development and external validation of a post-discharge bleeding risk score in patients with acute coronary syndrome: The BleeMACS score. International Journal of Cardiology, 2018, 254, 10-15.	1.7	66
61	Prognosis of elderly patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention in 2001 to 2011: A report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) registry. American Heart Journal, 2014, 167, 666-673.	2.7	65
62	External Validation of the DAPT Score in a Nationwide Population. Journal of the American College of Cardiology, 2018, 72, 1069-1078.	2.8	63
63	Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. European Heart Journal, 2021, 42, 1742-1756.	2.2	63
64	The Antibody Configurations of Cardiac Troponin I Assays May Determine Their Clinical Performance. Clinical Chemistry, 2006, 52, 832-837.	3.2	62
65	Relationship Between Cancer and Cardiovascular Outcomes Following Percutaneous Coronary Intervention. Journal of the American Heart Association, 2015, 4, .	3.7	62
66	Short Duration of DAPT Versus De-Escalation After Percutaneous Coronary Intervention for AcuteÂCoronaryÂSyndromes. JACC: Cardiovascular Interventions, 2022, 15, 268-277.	2.9	62
67	Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization. Circulation, 2016, 133, 39-47.	1.6	58
68	Direct or subacute coronary angiography in out-of-hospital cardiac arrest (DISCO)â€"An initial pilot-study of a randomized clinical trial. Resuscitation, 2019, 139, 253-261.	3.0	58
69	Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes. JAMA Cardiology, 2018, 3, 1160.	6.1	57
70	An acute inflammatory reaction induced by myocardial damage is superimposed on a chronic inflammation in unstable coronary artery disease. American Heart Journal, 2005, 149, 619-626.	2.7	56
71	Impact of chronic obstructive pulmonary disease on morbidity and mortality after myocardial infarction. Open Heart, 2014, 1, e000002.	2.3	56
72	DETermination of the role of OXygen in suspected Acute Myocardial Infarction trial. American Heart Journal, 2014, 167, 322-328.	2.7	56

#	Article	IF	Citations
73	Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention. Heart, 2016, 102, 617-625.	2.9	56
74	Therapeutic Hypothermia for the Treatment of Acute Myocardial Infarctionâ€“Combined Analysis of the RAPID MI-ICE and the CHILL-MI Trials. Therapeutic Hypothermia and Temperature Management, 2015, 5, 77-84.	0.9	54
75	Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study. American Heart Journal, 2019, 209, 97-105.	2.7	53
76	Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes. European Heart Journal, 2020, 41, 3132-3140.	2.2	52
77	European Society of Cardiology methodology for the development of quality indicators for the quantification of cardiovascular care and outcomes. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 4-13.	4.0	52
78	Potent P2Y 12 Inhibitors in MenÂVersusÂWomen. Journal of the American College of Cardiology, 2017, 69, 1549-1559.	2.8	51
79	Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI. Journal of the American College of Cardiology, 2020, 76, 162-171.	2.8	50
80	Heart Failure Complicating Nonâ€“ST-Segment Elevation Acute Coronary Syndrome. JACC: Heart Failure, 2013, 1, 223-229.	4.1	48
81	Ticagrelor Effects on Myocardial Infarction and the Impact of Event Adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) Trial. Journal of the American College of Cardiology, 2014, 63, 1493-1499.	2.8	47
82	Î²â€Blocker Use and Mortality in COPD Patients After Myocardial Infarction: A Swedish Nationwide Observational Study. Journal of the American Heart Association, 2015, 4, .	3.7	46
83	Treatment Patterns and Outcomes in Patients Undergoing Percutaneous Coronary Intervention Treated With Prasugrel or Clopidogrel (from the Swedish Coronary Angiography and Angioplasty) Tj ETQq1 1 0.784314 rgBT /Overloc	3.1	46
84	Cardiac troponin I levels in patients with nonâ€“ST-elevation acute coronary syndromeâ€”The importance of gender. American Heart Journal, 2014, 168, 317-324.e1.	2.7	44
85	Long-Term Outcome of Incomplete Revascularization After Percutaneous Coronary Intervention in SCAAR (Swedish Coronary Angiography and Angioplasty Registry). JACC: Cardiovascular Interventions, 2016, 9, 207-215.	2.9	43
86	Biomarkers for risk stratification of patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: Insights from the Platelet Inhibition and Patient Outcomes trial. American Heart Journal, 2015, 169, 879-889.e7.	2.7	42
87	Contemporary use of ticagrelor in patients with acute coronary syndrome: insights from Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). European Heart Journal - Cardiovascular Pharmacotherapy, 2016, 2, 5-12.	3.0	40
88	Incidence and outcome of myocardial infarction treated with percutaneous coronary intervention during COVID-19 pandemic. Heart, 2020, 106, 1812-1818.	2.9	40
89	Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes. Heart, 2014, 100, 1762-1769.	2.9	38
90	Novel Trial Designs: Lessons Learned from Thrombus Aspiration During ST-Segment Elevation Myocardial Infarction in Scandinavia (TASTE) Trial. Current Cardiology Reports, 2016, 18, 11.	2.9	38

#	Article	IF	Citations
91	Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Journal of the American Heart Association, 2015, 4, e002490.	3.7	37
92	Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes. American Heart Journal, 2017, 186, 91-99.	2.7	36
93	Angiographic Outcomes in the PLATO TrialÂ(Platelet Inhibition and PatientÂOutcomes). JACC: Cardiovascular Interventions, 2013, 6, 671-683.	2.9	35
94	The prevalence and prognostic importance of possible familial hypercholesterolemia in patients with myocardial infarction. American Heart Journal, 2016, 181, 35-42.	2.7	35
95	Realâ€life clinical outcomes with everolimus eluting platinum chromium stent with an abluminal biodegradable polymer in patients from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Catheterization and Cardiovascular Interventions, 2017, 90, 881-887.	1.7	35
96	Trial Design Principles for Patients at HighÂBleeding Risk Undergoing PCI. Journal of the American College of Cardiology, 2020, 76, 1468-1483.	2.8	35
97	Effects of supplemental oxygen therapy in patients with suspected acute myocardial infarction: a meta-analysis of randomised clinical trials. Heart, 2018, 104, 1691-1698.	2.9	34
98	Coronary angiography in out-of-hospital cardiac arrest without ST elevation on ECGâ€”Short- and long-term survival. American Heart Journal, 2018, 200, 90-95.	2.7	34
99	Instantaneous Wave-Free Ratio versus Fractional Flow Reserve guided intervention (iFR-SWEDEHEART): Rationale and design of a multicenter, prospective, registry-based randomized clinical trial. American Heart Journal, 2015, 170, 945-950.	2.7	32
100	Oxygen therapy in ST-elevation myocardial infarction. European Heart Journal, 2018, 39, 2730-2739.	2.2	32
101	Long-Term Incidence of Atrial Fibrillation and Stroke Among Cross-Country Skiers: Cohort Study of Endurance-Trained Male and Female Athletes. Circulation, 2019, 140, 910-920.	1.6	32
102	Bivalirudin versus heparin in non-ST and ST-segment elevation myocardial infarctionâ€”a registry-based randomized clinical trial in the SWEDEHEART registry (the VALIDATE-SWEDEHEART trial). American Heart Journal, 2016, 175, 36-46.	2.7	31
103	Amyotrophic lateral sclerosis among cross-country skiers in Sweden. European Journal of Epidemiology, 2016, 31, 247-253.	5.7	31
104	Midlife physical activity is associated with lower incidence of vascular dementia but not Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2019, 11, 87.	6.2	30
105	Percutaneous Treatment and Outcomes of Small Coronary Vessels. JACC: Cardiovascular Interventions, 2020, 13, 793-804.	2.9	30
106	5-Year Outcomes of PCI Guided by Measurement of Instantaneous Wave-Free Ratio Versus Fractional FlowÂReserve. Journal of the American College of Cardiology, 2022, 79, 965-974.	2.8	30
107	A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study. American Heart Journal, 2016, 174, 120-128.	2.7	29
108	Outcomes in patients treated with ticagrelor versus clopidogrel after acute myocardial infarction stratified by renal function. Heart, 2018, 104, 1575-1582.	2.9	29

#	Article	IF	Citations
109	Impact of Selection Bias on Estimation of Subsequent Event Risk. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	28
110	Low risk pragmatic trials do not always require participantsâ€™ informed consent. BMJ: British Medical Journal, 2019, 364, l1092.	2.3	28
111	The Acute S<u>t</u>roke or Transient Isc<u>h</u>emic Attack Treated with Tic<u>a</u>gre<u>l</u>or and Aspirin for Pr<u>e</u>vention of <u>S</u>troke and Death (THALES) trial: Rationale and design. International Journal of Stroke, 2019, 14, 745-751.	5.9	28
112	Patient-tailored antithrombotic therapy following percutaneous coronary intervention. European Heart Journal, 2021, 42, 1038-1046.	2.2	28
113	Growth Differentiation Factor 15 at 1ÂMonth After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding. Journal of the American Heart Association, 2017, 6, .	3.7	27
114	Clinical impact of direct stenting and interaction with thrombus aspiration in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: Thrombectomy Trialists Collaboration. European Heart Journal, 2018, 39, 2472-2479.	2.2	27
115	Clinical use of cangrelor: nationwide experience from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 151-157.	3.0	27
116	Survival of Patients With Angina Pectoris Undergoing Percutaneous Coronary Intervention With Intracoronary Pressure Wire Guidance. Journal of the American College of Cardiology, 2020, 75, 2785-2799.	2.8	27
117	Impaired Fibrinolysis Predicts Adverse Outcome in Acute Coronary Syndrome Patients with Diabetes: A PLATO Sub-Study. Thrombosis and Haemostasis, 2020, 120, 412-422.	3.4	27
118	Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Nonâ€“ST-Elevation Acute Coronary Syndrome. Clinical Chemistry, 2017, 63, 573-584.	3.2	26
119	Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome. American Heart Journal, 2017, 187, 194-203.	2.7	26
120	Design of DISCOâ€”Direct or Subacute Coronary Angiography in Out-of-Hospital Cardiac Arrest study. American Heart Journal, 2018, 197, 53-61.	2.7	26
121	SWEDEHEART Annual Report 2012. Scandinavian Cardiovascular Journal, 2014, 48, 1-1.	1.2	25
122	No Benefit of Ticagrelor Pretreatment Compared With Treatment During Percutaneous Coronary Intervention in Patients With ST-Segmentâ€“Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2018, 11, e005528.	3.9	25
123	Integrating the results of the CULPRIT-SHOCK trial in the 2017 ESC ST-elevation myocardial infarction guidelines: viewpoint of the task force. European Heart Journal, 2018, 39, 4239-4242.	2.2	25
124	Short and long-term survival after primary percutaneous coronary intervention in young patients with ST-elevation myocardial infarction. International Journal of Cardiology, 2016, 203, 697-701.	1.7	24
125	Antithrombotic agents for secondary prevention after acute coronary syndromes: A systematic review and network meta-analysis. International Journal of Cardiology, 2017, 241, 87-96.	1.7	24
126	Shortâ€•and Longâ€Term Clinical Outcomes for Patients With Takotsubo Syndrome and Patients With Myocardial Infarction: A Report From the Swedish Coronary Angiography and Angioplasty Registry. Journal of the American Heart Association, 2021, 10, e017290.	3.7	24

#	Article	IF	Citations
127	Risk of Recurrent Stroke and Death After First Stroke in Longâ€Distance Ski Race Participants. Journal of the American Heart Association, 2015, 4, e002469.	3.7	23
128	Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. American Heart Journal, 2016, 177, 1-8.	2.7	23
129	Bleeding after antiplatelet therapy for the treatment of acute coronary syndromes: a review of the evidence and evolving paradigms. Expert Opinion on Drug Safety, 2019, 18, 1171-1189.	2.4	23
130	Ten-year all-cause death after percutaneous or surgical revascularization in diabetic patients with complex coronary artery disease. European Heart Journal, 2021, 43, 56-67.	2.2	23
131	STâ€Elevation Myocardial Infarction, Thrombus Aspiration, and Different Invasive Strategies. A TASTE Trial Substudy. Journal of the American Heart Association, 2015, 4, e001755.	3.7	22
132	Long-Term Effects of Oxygen Therapy on Death or Hospitalization for Heart Failure in Patients With Suspected Acute Myocardial Infarction. Circulation, 2018, 138, 2754-2762.	1.6	22
133	Coronary Artery Perforation and Tamponadeâ€€â€• Incidence, Risk Factors, Predictors and Outcomes From 12 Yearsâ€™ Data of the SCAAR Registry â€•. Circulation Journal, 2019, 84, 43-53.	1.6	22
134	The need for increased pragmatism in cardiovascular clinical trials. Nature Reviews Cardiology, 2022, 19, 737-750.	13.7	22
135	Cancer incidence in participants in a long-distance ski race (Vasaloppet, Sweden) compared to the background population. European Journal of Cancer, 2015, 51, 558-568.	2.8	21
136	Survival and incidence of cardiovascular diseases in participants in a long-distance ski race (Vasaloppet, Sweden) compared with the background population. European Heart Journal Quality of Care & Clinical Outcomes, 2018, 4, 91-97.	4.0	20
137	Admission Levels of DKK1 (Dickkopf-1) Are Associated With Future Cardiovascular Death in Patients With Acute Coronary Syndromes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 294-302.	2.4	20
138	Improving public health by improving clinical trial guidelines and their application. European Heart Journal, 2017, 38, 1632-1637.	2.2	19
139	Cangrelor in combination with ticagrelor provides consistent and potent P2Y12-inhibition during and after primary percutaneous coronary intervention in real-world patients with ST-segment-elevation myocardial infarction. Platelets, 2017, 28, 414-416.	2.3	19
140	Editorâ€™s Choice- Heparin pre-treatment in patients with ST-segment elevation myocardial infarction and the risk of intracoronary thrombus and total vessel occlusion. Insights from the TASTE trial. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 15-23.	1.0	19
141	Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. American Heart Journal, 2014, 168, 68-75.e2.	2.7	18
142	Platelet-related biomarkers and their response to inhibition with aspirin and p2y12-receptor antagonists in patients with acute coronary syndrome. Journal of Thrombosis and Thrombolysis, 2017, 44, 145-153.	2.1	18
143	Risk Assessment Using Risk Scores in Patients with Acute Coronary Syndrome. Journal of Clinical Medicine, 2020, 9, 3039.	2.4	18
144	Polymorphism of the cystatin C gene in patients with acute coronary syndromes: Results from the PLATelet inhibition and patient Outcomes study. American Heart Journal, 2014, 168, 96-102.e2.	2.7	17

#	Article	IF	Citations
145	Risk of recurrent ischaemic events after myocardial infarction in long-distance ski race participants. European Journal of Preventive Cardiology, 2016, 23, 282-290.	1.8	17
146	Outcomes after planned invasive or conservative treatment strategy in patients with non-ST-elevation acute coronary syndrome and a normal value of high sensitivity troponin at randomisation: A Platelet Inhibition and Patient Outcomes (PLATO) trial biomarker substudy. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 500-510.	1.0	17
147	Clinical and angiographic outcomes of bioabsorbable vs. permanent polymer drug-eluting stents in Sweden: a report from the Swedish Coronary and Angioplasty Registry (SCAAR). European Heart Journal, 2019, 40, 2607-2615.	2.2	17
148	Subsequent Event Risk in Individuals With Established Coronary Heart Disease. Circulation Genomic and Precision Medicine, 2019, 12, e002470.	3.6	17
149	Ticagrelor Added to Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack in Prevention of Disabling Stroke. JAMA Neurology, 2021, 78, 177.	9.0	17
150	Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in nonâ€“STâ€segment elevation acute coronary syndrome in the PLATO trial. Clinical Cardiology, 2017, 40, 390-398.	1.8	16
151	Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease. Kidney International, 2017, 91, 216-226.	5.2	16
152	Impact of Thrombus Aspiration on Mortality, Stent Thrombosis, and Stroke in Patients With STâ€Segmentâ€“Elevation Myocardial Infarction: A Report From the Swedish Coronary Angiography and Angioplasty Registry. Journal of the American Heart Association, 2018, 7, .	3.7	16
153	Interleukinâ€18 in patients with acute coronary syndromes. Clinical Cardiology, 2019, 42, 1202-1209.	1.8	16
154	Assessing the Nationwide Impact of a Registry-Based Randomized Clinical Trial on Cardiovascular Practice. Circulation: Cardiovascular Interventions, 2019, 12, e007381.	3.9	16
155	Radial artery access is associated with lower mortality in patients undergoing primary PCI: a report from the SWEDEHEART registry. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 323-332.	1.0	16
156	No-touch saphenous vein grafts in coronary artery surgery (SWEDEGRAFT): Rationale and design of a multicenter, prospective, registry-based randomized clinical trial. American Heart Journal, 2020, 224, 17-24.	2.7	16
157	Development and validation of an artificial neural network algorithm to predict mortality and admission to hospital for heart failure after myocardial infarction: a nationwide population-based study. The Lancet Digital Health, 2022, 4, e37-e45.	12.3	16
158	Gender differences in utilization of coronary angiography and angiographic findings after out-of-hospital cardiac arrest: A registry study. Resuscitation, 2019, 143, 189-195.	3.0	15
159	Elevated admission glucose is common and associated with high short-term complication burden after acute myocardial infarction: Insights from the VALIDATE-SWEDEHEART study. Diabetes and Vascular Disease Research, 2019, 16, 582-584.	2.0	15
160	Effect of Oxygen Therapy on Cardiovascular Outcomes in Relation to Baseline Oxygen Saturation. JACC: Cardiovascular Interventions, 2020, 13, 502-513.	2.9	15
161	Comparison of warfarin versus antiplatelet therapy after surgical bioprosthetic aortic valve replacement. Heart, 2020, 106, 838-844.	2.9	15
162	Ranolazine After Incomplete Percutaneous Coronary Revascularization in Patients With Versus Without Diabetes Mellitus. Journal of the American College of Cardiology, 2017, 69, 2304-2313.	2.8	14

#	Article	IF	Citations
163	Antithrombotic therapy after myocardial infarction in patients with atrial fibrillation undergoing percutaneous coronary intervention. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 36-45.	3.0	14
164	Long distance ski racing is associated with lower long-term incidence of depression in a population based, large-scale study. Psychiatry Research, 2019, 281, 112546.	3.3	14
165	Helicobacter pylori screening in clinical routine during hospitalization for acute myocardial infarction. American Heart Journal, 2021, 231, 105-109.	2.7	14
166	Follow-up of ischaemic heart disease in patients with coeliac disease. European Journal of Preventive Cardiology, 2015, 22, 83-90.	1.8	13
167	The Analgesic Effect of Oxygen in Suspected Acute Myocardial Infarction. JACC: Cardiovascular Interventions, 2018, 11, 1590-1597.	2.9	13
168	Physical Activity Reduces Epilepsy Incidence: a Retrospective Cohort Study in Swedish Cross-Country Skiers and an Experimental Study in Seizure-Prone Synapsin II Knockout Mice. Sports Medicine - Open, 2019, 5, 52.	3.1	13
169	Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin versus Heparin in Acute Myocardial Infarction: Rationale and Methodology. Thrombosis and Haemostasis, 2020, 120, 348-362.	3.4	13
170	The SCAAR-scare in perspective. EuroIntervention, 2009, 5, 501-504.	3.2	13
171	The 2017 ESC STEMI Guidelines. European Heart Journal, 2018, 39, 79-82.	2.2	12
172	Prognostic impact of baseline inflammatory markers in patients with acute coronary syndromes treated with ticagrelor and clopidogrel. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 153-163.	1.0	12
173	Design and rationale of TROCADERO: A TRial Of Caffeine to Alleviate DyspnEa Related to ticagrelOr. American Heart Journal, 2015, 170, 465-470.	2.7	11
174	Prevalence and relevance of abnormal glucose metabolism in acute coronary syndromes: insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. Journal of Thrombosis and Thrombolysis, 2019, 48, 563-569.	2.1	11
175	Delayed Clinical Manifestation of Parkinsonâ€™s Disease Among Physically Active: Do Participants in a Long-Distance Ski Race Have a Motor Reserve?1. Journal of Parkinson's Disease, 2020, 10, 267-274.	2.8	11
176	Association of Factor V Leiden With Subsequent Atherothrombotic Events. Circulation, 2020, 142, 546-555.	1.6	11
177	Physical Activity Is Associated With Lower Long-Term Incidence of Anxiety in a Population-Based, Large-Scale Study. Frontiers in Psychiatry, 2021, 12, 714014.	2.6	11
178	Efficacy and Safety of Ticagrelor and Aspirin in Patients With Moderate Ischemic Stroke. JAMA Neurology, 2021, 78, 1091.	9.0	11
179	The design can limit PRECIS-2 retrospective assessment of the clinical trial explanatory/pragmatic features. Journal of Clinical Epidemiology, 2020, 126, 193-201.	5.0	11
180	Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome. International Journal of Cardiology, 2014, 170, e59-e62.	1.7	10

#	Article	IF	Citations
181	Baseline Q Waves and Time From Symptom Onset to ST-segment Elevation Myocardial Infarction: Insights From PLATO on the Influence of Sex. American Journal of Medicine, 2015, 128, 914.e11-914.e19.	1.5	10
182	Impact of thrombus aspiration during ST-Elevation Myocardial Infarction: a six month composite endpoint and risk of stroke analyses of the TASTE trial. BMC Cardiovascular Disorders, 2016, 16, 62.	1.7	10
183	Coronary angiographic findings and outcomes in patients with sudden cardiac arrest without ST-elevation myocardial infarction: A SWEDEHEART study. Resuscitation, 2018, 126, 172-178.	3.0	10
184	Predictive Value of High-Sensitivity Troponin T for Systolic Dysfunction and Infarct Size (Six Months) After ST-Elevation Myocardial Infarction. American Journal of Cardiology, 2018, 122, 735-743.	1.6	10
185	Impact of chronic obstructive pulmonary disease on 10-year mortality after percutaneous coronary intervention and bypass surgery for complex coronary artery disease: insights from the SYNTAX Extended Survival study. Clinical Research in Cardiology, 2021, 110, 1083-1095.	3.3	10
186	Benchmarking Observational Analyses Before Using Them to Address Questions Trials Do Not Answer: An Application to Coronary Thrombus Aspiration. American Journal of Epidemiology, 2022, 191, 1652-1665.	3.4	10
187	Anticoagulant therapy and outcomes in patients with prior or acute heart failure and acute coronary syndromes: Insights from the APixaban for PRevention of Acute ISchemic Events 2 trial. American Heart Journal, 2015, 169, 531-538.	2.7	9
188	Low real-world early stent thrombosis rates in ST-elevation myocardial infarction patients and the use of bivalirudin, heparin alone or glycoprotein IIb/IIIa inhibitor treatment: A nationwide Swedish registry report. American Heart Journal, 2016, 176, 78-82.	2.7	9
189	Bioresorbable Stents in PCI. Current Cardiology Reports, 2016, 18, 74.	2.9	9
190	Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome. American Heart Journal, 2018, 201, 25-32.	2.7	9
191	P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes. JAMA Cardiology, 2019, 4, 680.	6.1	9
192	Bivalirudin Versus Heparin Monotherapy in Elderly Patients With Myocardial Infarction. Circulation: Cardiovascular Interventions, 2020, 13, e008671.	3.9	9
193	Good general health and lack of family history influence the underestimation of cardiovascular risk: a cross-sectional study. European Journal of Cardiovascular Nursing, 2021, 20, 676-683.	0.9	9
194	Differential effect of clopidogrel and ticagrelor on leukocyte count in relation to patient characteristics, biomarkers and genotype: a PLATO substudy. Platelets, 2022, 33, 425-431.	2.3	9
195	Ischemic Benefit and Hemorrhage Risk of Ticagrelor-Aspirin Versus Aspirin in Patients With Acute Ischemic Stroke or Transient Ischemic Attack. Stroke, 2021, 52, 3482-3489.	2.0	9
196	Obesity, Diabetes, and Acute Coronary Syndrome: Differences Between Asians and Whites. American Journal of Medicine, 2017, 130, 1170-1176.	1.5	8
197	Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient) Tj ETQq1 1 0.784314 rgBT /Overl	8.4	
198	Bivalirudin versus heparin monotherapy in non-ST-segment elevation myocardial infarction. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 492-501.	1.0	8

#	Article	IF	Citations
199	Income is associated with the probability to receive early coronary angiography after out-of-hospital cardiac arrest. Resuscitation, 2020, 156, 35-41.	3.0	8
200	Timing of coronary angiography in patients with non-ST-elevation acute coronary syndrome: long-term clinical outcomes from the nationwide SWEDEHEART registry. EuroIntervention, 2022, 18, 582-589.	3.2	8
201	Treatment Trends, Effectiveness, and Safety of Statins on Lipid Goal Attainment in Chinese Percutaneous Coronary Intervention Patients: a Multicenter, Retrospective Cohort Study. Clinical Therapeutics, 2017, 39, 1827-1839.e1.	2.5	7
202	Decreased Hip, Lower Leg, and Humeral Fractures but Increased Forearm Fractures in Highly Active Individuals. Journal of Bone and Mineral Research, 2018, 33, 1842-1850.	2.8	7
203	Oxygen Therapy in Myocardial Infarction Patients With or Without Diabetes: A Predefined Subgroup Analysis From the DETO2X-AMI Trial. Diabetes Care, 2019, 42, 2032-2041.	8.6	7
204	Ticagrelor in patients with heart failure after acute coronary syndromesâ€”Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. American Heart Journal, 2019, 213, 57-65.	2.7	7
205	Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines. Cardiology Journal, 2020, 27, 661-676.	1.2	7
206	Bivalirudin Versus Heparin Monotherapy in ST-Segmentâ€“Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2021, 14, e008969.	3.9	7
207	Time Course for Benefit and Risk of Ticagrelor and Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack. Neurology, 2022, 99, .	1.1	7
208	Ticagrelor in Patients With Acute Coronary Syndromes and Stroke. Stroke, 2013, 44, 1477-1479.	2.0	6
209	Renal function is associated with long-term outcomes independent of degree of atherosclerosis: 6-year data from the Swedish Coronary Angiography and Angioplasty Registry. European Heart Journal Quality of Care & Clinical Outcomes, 2016, 2, 91-98.	4.0	6
210	Response by Jolly et al to Letters Regarding Article, â€œThrombus Aspiration in ST-Segment-Elevation Myocardial Infarction: An Individual Patient Meta-Analysis: Thrombectomy Trialists Collaborationâ€• Circulation, 2017, 135, e1103-e1104.	1.6	6
211	Long-Distance Skiing and Incidence of Hypertension. Circulation, 2020, 141, 743-750.	1.6	6
212	Next-Generation Sequencing of CYP2C19 in Stent Thrombosis: Implications for Clopidogrel Pharmacogenomics. Cardiovascular Drugs and Therapy, 2021, 35, 549-559.	2.6	6
213	Routine Oxygen Therapy Does Not Improve Health-Related Quality of Life in Patients With Acute Myocardial Infarctionâ€”Insights From the Randomized DETO2X-AMI Trial. Frontiers in Cardiovascular Medicine, 2021, 8, 638829.	2.4	6
214	Differences in the 2020 ESC Versus 2015 ESC and 2014 ACC/AHA Guidelines on the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation. Current Atherosclerosis Reports, 2021, 23, 77.	4.8	6
215	Evidence-based treatments for STEMI: are we doing enough?. Lancet, The, 2013, 382, 576-579.	13.7	5
216	Frequency, clinical and angiographic characteristics, and outcomes of high-risk non-ST-segment elevation acute coronary syndromes patients with left circumflex culprit lesions. International Journal of Cardiology, 2016, 203, 708-713.	1.7	5

#	Article	IF	Citations
217	Thrombus aspiration in patients with large anterior myocardial infarction. American Heart Journal, 2016, 172, 129-134.	2.7	5
218	Bleeding associated with the management of acute coronary syndromes. Heart, 2017, 103, 546-562.	2.9	5
219	ALCAM predicts future cardiovascular death in acute coronary syndromes: Insights from the PLATO trial. Atherosclerosis, 2020, 293, 35-41.	0.8	5
220	Causes, pattern, predictors, and prognostic implications of new hospitalizations after transcatheter aortic valve implantation: a long-term nationwide observational study. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 150-160.	4.0	5
221	Safety of early hospital discharge following admission with ST-elevation myocardial infarction treated with percutaneous coronary intervention: a nationwide cohort study. EuroIntervention, 2022, 17, 1091-1099.	3.2	5
222	No misrepresentation of vital status follow-up in PLATO: Predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial. International Journal of Cardiology, 2014, 176, 300-302.	1.7	4
223	Percutaneous Closure in Transfemoral Aortic Valve Implantation: A Single-Centre Experience. CardioVascular and Interventional Radiology, 2015, 38, 1438-1443.	2.0	4
224	Coronary thrombus aspiration: a lesson for clinical medicine. Lancet, The, 2016, 387, 97-98.	13.7	4
225	Time-based measures of treatment effect: reassessment of ticagrelor and clopidogrel from the PLATO trial. Open Heart, 2017, 4, e000557.	2.3	4
226	New Method for Assessing the Effect of Driving Distance to Hospital Care. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	2.2	4
227	Caffeine and incidence of dyspnea in patients treated with ticagrelor. American Heart Journal, 2018, 200, 141-143.	2.7	4
228	Routine Oxygen Supplementation in Acute Cardiovascular Disease. Circulation, 2018, 137, 320-322.	1.6	4
229	Bivalirudin versus heparin with primary percutaneous coronary intervention. American Heart Journal, 2018, 201, 9-16.	2.7	4
230	Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.7	4
231	Equilibrative nucleoside transporter 1 gene polymorphisms and clinical outcomes following acute coronary syndromes: findings from the PLATelet inhibition and patient Outcomes (PLATO) study. Platelets, 2019, 30, 579-588.	2.3	4
232	Radial versus femoral access in patients with acute coronary syndrome undergoing invasive management: A prespecified subgroup analysis from VALIDATE-SWEDEHEART. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 510-519.	1.0	4
233	Report of the European Society of Cardiology Cardiovascular Round Table regulatory workshop update of the evaluation of new agents for the treatment of acute coronary syndrome: Executive summary. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 745-754.	1.0	4
234	Patient experience of the informed consent process during acute myocardial infarction: a sub-study of the VALIDATE-SWEDEHEART trial. Trials, 2020, 21, 246.	1.6	4

#	Article	IF	Citations
235	Post-resuscitation myocardial dysfunction in out-of-hospital cardiac arrest patients randomized to immediate coronary angiography versus standard of care. IJC Heart and Vasculature, 2020, 27, 100483.	1.1	4
236	The Full Revasc (Ffr-gUidance for compLete non-cuLprit REVASCularization) Registry-based randomized clinical trial. American Heart Journal, 2021, 241, 92-100.	2.7	4
237	Costâ€“effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 777-785.	3.0	4
238	Coagulation, inflammation and myocardial dysfunction in unstable coronary artery disease and the influence of glycoprotein IIb/IIIa inhibition and low molecular weight heparin. Upsala Journal of Medical Sciences, 2004, 109, 71-122.	0.9	3
239	Biobank linked to SWEDEHEART quality registryâ€”routine blood sample collection opens new opportunities for cardiovascular research. Upsala Journal of Medical Sciences, 2019, 124, 12-15.	0.9	3
240	Relationship between degree of heparin anticoagulation and clinical outcome in patients receiving potent P2Y12-inhibitors with no planned glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention in acute myocardial infarction: a VALIDATE-SWEDEHEART substudy. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 6-13.	3.0	3
241	Low-dose ticagrelor with or without acetylsalicylic acid in patients with acute coronary syndrome: Rationale and design of the ELECTRA-SIRIO 2 trial. Cardiology Journal, 2021, , .	1.2	3
242	Clinical Outcomes After Surgical Revascularization Using No-Touch Versus Conventional Saphenous Vein Grafts: Mid-Term Follow-Up of Propensity Score Matched Cohorts. Seminars in Thoracic and Cardiovascular Surgery, 2021, , .	0.6	3
243	Sex as a determinant of prehospital ECG in ST- and non-ST elevation myocardial infarction patients: TableÂ1. Heart, 2014, 100, 1817-1818.	2.9	2
244	Height and prognosis following percutaneous coronary intervention. International Journal of Cardiology, 2016, 224, 188-190.	1.7	2
245	Importance of post-approval real-word evidence. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 10-11.	3.0	2
246	Discussion forum response from authors to letter regarding article, â€˜Three questions regarding the 2017 ESC STEMI guidelinesâ€™. European Heart Journal, 2019, 40, 1242-1242.	2.2	2
247	SWEDEHEART-1-year data show no benefit of newer generation drug-eluting stents over bare-metal stents in patients with severe kidney dysfunction following percutaneous coronary intervention. Coronary Artery Disease, 2020, 31, 49-58.	0.7	2
248	Outcome of PCI with Xience versus other commonly used modern drug eluting stents: A SCAAR report. Catheterization and Cardiovascular Interventions, 2021, 98, E197-E204.	1.7	2
249	Randomized comparison of early supplemental oxygen versus ambient air in patients with confirmed myocardial infarction: Sex-related outcomes from DETO2X-AMI. American Heart Journal, 2021, 237, 13-24.	2.7	2
250	Factor V Leiden and the Risk of Bleeding in Patients With Acute Coronary Syndromes Treated With Antiplatelet Therapy: Pooled Analysis of 3 Randomized Clinical Trials. Journal of the American Heart Association, 2021, 10, e021115.	3.7	2
251	Effects of early myocardial reperfusion and perfusion on myocardial necrosis/dysfunction and inflammation in patients with ST-segment and non-ST-segment elevation acute coronary syndrome: results from the PLATelet inhibition and patients Outcomes (PLATO) trial. European Heart Journal: Acute Cardiovascular Care, 2022, 11, 336-349.	1.0	2
252	Ischaemic Events and Stent Thrombosis following Planned Discontinuation of Study Treatment with Ticagrelor or Clopidogrel in the PLATO Study. Thrombosis and Haemostasis, 2018, 118, 427-429.	3.4	1

#	Article	IF	Citations
253	â€˜Ten Commandmentsâ€™ of the 2017 ESC STEMI Guidelines. European Heart Journal, 2018, 39, 83-83.	2.2	1
254	Short-term mental distress in research participants after receiving cardiovascular risk information. PLoS ONE, 2019, 14, e0217247.	2.5	1
255	Response to letter regarding article, â€˜Oxygen therapy in ST-elevation myocardial infarctionâ€™. European Heart Journal, 2019, 40, 215-215.	2.2	1
256	Haemorrhagic stroke and major bleeding after intervention with biological aortic valve prosthesis: risk factors and antithrombotic treatment. European Heart Journal Supplements, 2020, 22, C26-C33.	0.1	1
257	Response by Navarese et al to Letters Regarding Article, â€œComparative Efficacy and Safety of Oral P2Y12 Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52â€‰816 Patients From 12 Randomized Trialsâ€• Circulation, 2021, 143, e236-e237.	1.6	1
258	Pre-operative heart failure worsens outcome after aortic valve replacement irrespective of left ventricular ejection fraction. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 127-134.	4.0	1
259	Communicating Test Results from a General Health Check: Preferences from a Discrete Choice Experiment Survey. Patient, 2021, 14, 649-660.	2.7	1
260	Assessing the external validity of the VALIDATE-SWEDEHEART trial. Clinical Trials, 2021, 18, 427-435.	1.6	1
261	Individualized Duration of Dual Antiplatelet Therapy Guided by Risk Scoresã€€â€• Ready for Prime Time? â€•. Circulation Journal, 2020, 84, 153-155.	1.6	1
262	Myocardial infarction after elective percutaneous coronary interventionâ€”which cardiac troponin cut-off to use?. European Heart Journal, 2021, , .	2.2	1
263	What CVD risk factors predict self-perceived risk of having a myocardial infarction? A cross-sectional study. International Journal of Cardiology Cardiovascular Risk and Prevention, 2022, 12, 200125.	1.1	1
264	Balance of Benefit and Risk of Ticagrelor in Patients With Diabetes and Stable Coronary Artery Disease According to Bleeding Risk Assessment With the CRUSADE Score: Data From THEMIS and THEMIS PCI. American Heart Journal, 2022, 249, 23-23.	2.7	1
265	Improving long-term outcome after myocardial infarction. Lancet, The, 2012, 380, 1290-1291.	13.7	0
266	Evidenced-Based Antithrombotic Therapy for Acute Coronary Syndromes. Diabetes, 2013, 62, 709-710.	0.6	0
267	Response to the letter to the editor by Ariza-SolÃ© et al. American Heart Journal, 2014, 168, e5.	2.7	0
268	Unreliable Observations from a Confounded Analysis of a Skewed Database. American Journal of Medicine, 2017, 130, e355-e356.	1.5	0
269	Nonâ€“Vitamin K Antagonist Preferred in Patients With Nonvalvular Atrial Fibrillation and Indication for Aspirin Therapy. Circulation, 2018, 137, 1130-1131.	1.6	0
270	How far will the FIREHAWK stent fly?. Lancet, The, 2018, 392, 1091-1092.	13.7	0

#	Article	IF	Citations
271	Clinical Impact of Intraprocedural Stent Thrombosis During Percutaneous Coronary Intervention in Patients Treated With Potent P2Y12 inhibitors â€•a VALIDATEâ€SWEDEHEART Substudy. Journal of the American Heart Association, 2021, 10, e022984.	3.7	0
272	Avoiding Routine Oxygen Therapy in Patients With Myocardial Infarction Saves Significant Expenditure for the Health Care Systemâ€"Insights From the Randomized DETO2X-AMI Trial. Frontiers in Public Health, 2021, 9, 711222.	2.7	0